The reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.62BCNY
242.24M · vs all stocks (USD)
Updated Oct 24, 2026
Revenue (TTM)
136.13MCNY
20.42M · vs all stocks (USD)
Updated Oct 24, 2026
Profit Margin
-98.48%
vs Biotechnology peers
Updated Oct 24, 2026
Beta
0.2140x
vs all stocks
Updated Oct 24, 2026
52-Week Change
-30.68%
vs all stocks
Updated Oct 24, 2026
Market Capitalization
1.62BCNY
242.24M · vs all stocks (USD)
Updated Oct 24, 2026
Enterprise Value
1.25BCNY
188.08M · vs all stocks (USD)
Updated Oct 24, 2026
Price to Sales (TTM)
11.87x
vs Biotechnology peers
Updated Oct 24, 2026
Price to Book (MRQ)
2.05x
vs Biotechnology peers
Updated Oct 24, 2026
Enterprise to Revenue
9.21x
vs Biotechnology peers
Updated Oct 24, 2026
Enterprise to EBITDA
-19.92x
vs Biotechnology peers
Updated Oct 24, 2026
Gross Margin
6.12%
vs Biotechnology peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 15.86%.Updated Oct 24, 2026
Profit Margin
-98.48%
vs Biotechnology peers
Updated Oct 24, 2026
Operating Margin
-79.74%
vs Biotechnology peers
Updated Oct 24, 2026
Return on Assets (TTM)
-6.11%
vs Biotechnology peers
Updated Oct 24, 2026
Return on Equity (TTM)
-19.01%
vs Biotechnology peers
Updated Oct 24, 2026
Revenue (TTM)
136.13MCNY
20.42M · vs all stocks (USD)
Updated Oct 24, 2026
Revenue per Share (TTM)
0.4960CNYUpdated Oct 24, 2026
Quarterly Revenue Growth
41.30%
vs Biotechnology peers
Updated Oct 24, 2026
Gross Profit (TTM)
21.59MCNY
3.24M · vs all stocks (USD)
Updated Oct 24, 2026
EBITDA (TTM)
-62.95MCNY
-9.44M · vs all stocks (USD)
Updated Oct 24, 2026
Net Income (TTM)
-134.06MCNY
-20.11M · vs all stocks (USD)
Updated Oct 24, 2026
Quarterly Earnings Growth (YoY)
41.35%
vs Biotechnology peers
Updated Oct 24, 2026
Operating Cash Flow (TTM)
20.74MCNY
3.11M · vs all stocks (USD)
Updated Oct 24, 2026
Levered Free Cash Flow (TTM)
2.75MCNY
412.64K · vs all stocks (USD)
Updated Oct 24, 2026
Payout Ratio
17.03%
vs Biotechnology peers
Updated Oct 24, 2026
Minority Interest (Equity)
-71.14MCNYFY2025 · Dec 31, 2025
Revenue
141.93MCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
97.22MCNYFY2025 · Dec 31, 2025
Gross Profit
44.71MCNYFY2025 · Dec 31, 2025
Operating Income
-78.24MCNY
-11.74M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-132.75MCNYFY2025 · Dec 31, 2025
Income Tax Expense
17.01MCNYFY2025 · Dec 31, 2025
Net Income
-149.75MCNYFY2025 · Dec 31, 2025
EBIT
-129.17MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-38.98MCNYFY2025 · Dec 31, 2025
Research & Development
35.36MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
49.97MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
3.01MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
3.55MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
3.58MCNYFY2025 · Dec 31, 2025
EPS (Basic)
-0.4989CNYFY2025 · Dec 31, 2025
EPS (Diluted)
-0.4989CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
274.40MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
274.40MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-149.75MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
12.85MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
77.56MCNYFY2025 · Dec 31, 2025
Free Cash Flow
2.32MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
296.37MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-149.75MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
3.62MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
178.32MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
45.37MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-75.24MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-75.24MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
10.00MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-219.00MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-2.71MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-21.52MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-233.23MCNYFY2025 · Dec 31, 2025
Shares Outstanding
274.40MSharesUpdated Oct 24, 2026
Float Shares
148.61MSharesUpdated Oct 24, 2026
% Held by Insiders
50.82%
vs all stocks
Updated Oct 24, 2026
% Held by Institutions
1.30%
vs all stocks
Updated Oct 24, 2026
Total Cash (MRQ)
347.18MCNY
52.07M · vs all stocks (USD)
Updated Oct 24, 2026
Total Cash per Share (MRQ)
1.28CNYUpdated Oct 24, 2026
Total Debt (MRQ)
60.02MCNY
9.00M · vs all stocks (USD)
Updated Oct 24, 2026
Total Debt to Equity (MRQ)
0.0846x
vs Biotechnology peers
Updated Oct 24, 2026
Current Ratio (MRQ)
3.13x
vs Biotechnology peers
Updated Oct 24, 2026
Book Value per Share (MRQ)
2.89CNYUpdated Oct 24, 2026
Total Assets
809.47MCNY
121.40M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
399.83MCNYFY2025 · Dec 31, 2025
Total Liabilities
97.06MCNYFY2025 · Dec 31, 2025
Total Non-current Assets
409.64MCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
3.54MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
93.52MCNYFY2025 · Dec 31, 2025
Cash
297.66MCNYFY2025 · Dec 31, 2025
Cash Equivalents
3.86MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
301.52MCNYFY2025 · Dec 31, 2025
Accounts Receivable
36.03MCNYFY2025 · Dec 31, 2025
Inventory
35.88MCNYFY2025 · Dec 31, 2025
Accounts Payable
27.23MCNYFY2025 · Dec 31, 2025
Short-term Debt
10.03MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
10.64MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
274.40MCNYFY2025 · Dec 31, 2025
Retained Earnings
-660.22MCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
712.41MCNY
106.85M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
26.14MCNYFY2025 · Dec 31, 2025
52-Week Low
5.47CNYUpdated Oct 24, 2026
52-Week High
11.39CNYUpdated Oct 24, 2026
52-Week Change
-30.68%
vs all stocks
Updated Oct 24, 2026
Beta
0.2140x
vs all stocks
Updated Oct 24, 2026
50-Day MA
6.49CNYUpdated Oct 24, 2026
200-Day MA
7.49CNYUpdated Oct 24, 2026
Avg 10-Day Volume
2.20MSharesUpdated Oct 24, 2026
Avg 30-Day Volume
2.45MSharesUpdated Oct 24, 2026
Diluted EPS (TTM)
-0.4900CNYUpdated Oct 24, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 6.1%, lower than 95% of its Biotechnology peers (median 65.4%)Significant